‘Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM’ – Author's reply

Broman, Niklas; Feuth, Thijs; Oksi, Jarmo

doi:10.1016/j.cmi.2022.06.028

Cited by 2 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These studies also observed platelet degranulation, lymphocyte apoptosis in serum, likely due to the viral mode of entry into the cells 4,5,9,10 . During acute infection, overproduction of proinflammatory cytokines (IL-6, IL-1β, and TNF-α) induces a 'cytokine storm' elevating the risk of clot formation, platelet activation, and ultimately hypoxia and multiorgan failure leading to high patient mortality 9,12 . Accordingly, serum proteomics using a highly sensitive targeted assay identified proteins of inflammation, cardiometabolic, and neurologic diseases to contribute to disease severity 13 .…”

Section: Introductionmentioning

confidence: 99%

Complex changes in serum protein levels in COVID-19 convalescents

Pushalkar

Maity

et al. 2022

Preprint

View full text Add to dashboard Cite

The COVID-19 pandemic, triggered by severe acute respiratory syndrome coronavirus 2, has affected millions of people worldwide. Much research has been dedicated to our understanding of COVID-19 disease heterogeneity and severity, but less is known about recovery associated changes. To address this gap in knowledge, we quantified the proteome from serum samples from 29 recuperated COVID-19 patients and 29 age-, race-, and sex-matched healthy controls. Many proteins from pathways known to change upon acute COVID-19 illness, such as from the complement cascade, coagulation system, inflammation and adaptive immune system, had returned to levels seen in healthy controls. In comparison, we identified 22 and 15 proteins with significantly elevated and lowered levels, respectively, amongst recuperated COVID-19 cases compared to healthy controls. Some of the changes were similar to those observed for the acute phase of the disease, i.e. elevated levels of proteins from hemolysis, the adaptive immune systems, and inflammation. In contrast, some changes opposed those in the acute phase, e.g. elevated levels of CETP and APOA1 which function in lipid/cholesterol metabolism, and decreased levels of proteins from the complement cascade (e.g. C1R, C1, and VWF), the coagulation system (e.g. THBS1 and VWF), and the regulation of the actin cytoskeleton (e.g. PFN1 and CFL1) amongst recuperated COVID-19 cases. We speculate that some of these changes might originate from transient decreases in platelet counts upon recovery from the disease. Finally, we observed race-specific changes, e.g. with respect to immunoglobulins and cholesterol-metabolism-related proteins.

show abstract

Section: Introductionmentioning

confidence: 99%

Complex changes in serum protein levels in COVID-19 convalescents

Pushalkar

Maity

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

Complex changes in serum protein levels in COVID-19 convalescents

Pushalkar,

Wu,

Maity

et al. 2024

Sci Rep

View full text Add to dashboard Cite

The COVID-19 pandemic, triggered by severe acute respiratory syndrome coronavirus 2, has affected millions of people worldwide. Much research has been dedicated to our understanding of COVID-19 disease heterogeneity and severity, but less is known about recovery associated changes. To address this gap in knowledge, we quantified the proteome from serum samples from 29 COVID-19 convalescents and 29 age-, race-, and sex-matched healthy controls. Samples were acquired within the first months of the pandemic. Many proteins from pathways known to change during acute COVID-19 illness, such as from the complement cascade, coagulation system, inflammation and adaptive immune system, had returned to levels seen in healthy controls. In comparison, we identified 22 and 15 proteins with significantly elevated and lowered levels, respectively, amongst COVID-19 convalescents compared to healthy controls. Some of the changes were similar to those observed for the acute phase of the disease, i.e. elevated levels of proteins from hemolysis, the adaptive immune systems, and inflammation. In contrast, some alterations opposed those in the acute phase, e.g. elevated levels of CETP and APOA1 which function in lipid/cholesterol metabolism, and decreased levels of proteins from the complement cascade (e.g. C1R, C1S, and VWF), the coagulation system (e.g. THBS1 and VWF), and the regulation of the actin cytoskeleton (e.g. PFN1 and CFL1) amongst COVID-19 convalescents. We speculate that some of these shifts might originate from a transient decrease in platelet counts upon recovery from the disease. Finally, we observed race-specific changes, e.g. with respect to immunoglobulins and proteins related to cholesterol metabolism.

show abstract

‘Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM’ – Author's reply

Cited by 2 publications

References 2 publications

Complex changes in serum protein levels in COVID-19 convalescents

Complex changes in serum protein levels in COVID-19 convalescents

Complex changes in serum protein levels in COVID-19 convalescents

Contact Info

Product

Resources

About